Why Tiziana Life Sciences Ltd’s (TLSA) Stock Is Down 7.66%
As of Wednesday, July 15, Tiziana Life Sciences Ltd’s TLSA share price has dipped by 7.66%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Commentary & Analysis
Why Tiziana Life Sciences Ltd’s (TLSA) Stock Is Up 6.77%
As of Tuesday, July 14, Tiziana Life Sciences Ltd’s TLSA share price has surged by 6.77%, which has investors questioning if this is right time to sell.Michael Rose
Why Tiziana Life Sciences Ltd’s (TLSA) Stock Is Up 8.13%
As of Monday, July 13, Tiziana Life Sciences Ltd’s TLSA share price has surged by 8.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tiziana Life Sciences Ltd’s (TLSA) Stock Is Up 5.69%
As of Thursday, July 02, Tiziana Life Sciences Ltd’s TLSA share price has surged by 5.69%, which has investors questioning if this is right time to sell.Michael Rose
Why Tiziana Life Sciences Ltd’s (TLSA) Stock Is Up 6.02%
As of Thursday, June 18, Tiziana Life Sciences Ltd’s TLSA share price has surged by 6.02%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TLSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $137.1 | $208.8 | 25% |
|
| Shares Out (Mil) | 119.7 | 53.9 | 66% |
|
| Institutional Ownership | 3.8% | 93.1% | 4% |
|
| Float (Mil) | 65.4 | 41.4 | 53% |
|
| Beta | 0.44 | 0.95 | 25% |
|
| Avg Daily Volume (000s) | 663 | 614 | 63% |
|
| Price Change (52-week) |
(49.8%) | 45.3% | 20% |
|
| Growth | TLSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 6.8% | (10.2%) | 50% |
|
| EPS (5yr) | 10.3% | 15.7% | 48 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TLSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($44) | 24% |
|
| EPS (TTM) | ($0.156) | ($1.600) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($33) | 18% |
|
| Net Cash Flow (TTM) (Mil) | $0 | $2 | 44% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $156 | $174 | 24% |
|
| Valuation | TLSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.09 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TLSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (161.8%) | (47.2%) | 3% |
|
| ROE | (924.3%) | (54.2%) | 0% |
|
| Liabilities to Assets | 99.5% | 29.1% | 94% |
|
| F-Score | 1 | 2 | 1% |
|
Tiziana Life Sciences Ltd did not pass any screens on 10/16/2026.
